Non-Proliferative Diabetic Retinopathy
Conditions
Brief summary
The goal of this clinical trial is to learn if drug TNTL works to treat non-proliferative diabetic retinopathy in adults. It will also learn about the safety of drug TNTL. The main questions it aims to answer are: 1. Does drug TNTL can improve visual acuity and reduce the degree of retinopathy? 2. What medical problems do participants have when taking drug TNTL? Researchers will compare drug TNTL to a placebo (a look-alike substance that contains no drug) to see if drug TNTL works to treat non-proliferative diabetic retinopathy. Participants will: 1. Take drug TNTL or a placebo every day for 6 months 2. Visit the clinic once every 4 weeks for checkups and tests 3. Keep a diary of their symptoms and Change from baseline
Interventions
DRUGTNTL
oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
DRUGTNTL simulation preparation
oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
Sponsors
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age range of 18 to 75 years old (including boundary values); * Conform to the diagnosis of type 2 diabetes and diabetes retinopathy. diabetes retinopathy is classified as NPDR and mild and moderate patients; * Patients with the best corrected visual acuity (BCVA) of the target eye is ≥ 34 points (ETDRS visual acuity chart, visual acuity equivalent to a score of 20/200, decimal 0.1); * Patients who meet the syndrome differentiation criteria of Yin deficiency, internal heat, and eye meridian stasis in traditional Chinese medicine; * During the screening period, glycated hemoglobin (HbA1c) should be ≤ 8.5%; * Agree to participate in this clinical study and voluntarily sign the informed consent form.
Exclusion criteria
* Patients with no light perception in one eye; * Patients with macular edema who require anti Vascular Endothelial Growth Factor(VEGF) treatment; * People with other eye diseases, such as retinal artery or vein occlusion, non diabetes retinopathy, retinal detachment, uveitis, glaucoma, corneal ulcer, cataract affecting fundus examination, optic neuropathy and high myopia with fundus changes; * Patients with acute complications of diabetes (such as diabetes ketoacidosis, hyperglycemia hyperosmolality syndrome, diabetes lactic acidosis, etc.) within one year before the screening period; * People with other eye related complications of diabetes, such as iris neovascularization, angle neovascularization, and retinal neovascularization; * acupuncture and moxibustion and other external treatment methods of traditional Chinese medicine were used to treat diabetes retinopathy within one week before enrollment; * Patients who have used drugs clearly stated in the instruction manual to treat diabetes retinopathy, such as calcium dobesilate, pancreatic kallidinogenase, Qiming Granules, Shuangdan Mingmu Capsules, Compound Danshen Dropping Pills, Tongluo Mingmu Capsules, etc. within 2 weeks before enrollment; * Patients who have undergone glaucoma, vitreous, retinal and other intraocular surgeries and procedures in the target eye within 3 months before enrollment; * Patients who have undergone cataract surgery in the target eye within 3 months prior to enrollment and have not yet stabilized according to the researcher's assessment; * Patients who have received intravitreal injections of anti VEGF antibodies and glucocorticoids in the target eye within 3 months prior to enrollment; * Patients who have undergone total retinal laser photocoagulation treatment in the target eye; * For those whose refractive media is turbid and difficult to evaluate fundus images in the target eye; * Uncontrolled or controlled blood pressure with systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg; * When screening, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) should be ≥ 1.5 times the upper limit of normal value; * Patients with serious kidney disease (such as azotemia and uremia), diabetes foot, etc; * When screening, individuals with severe primary diseases such as respiratory, cardiovascular, cerebrovascular, endocrine, digestive, and hematopoietic systems, or those with severe mental illnesses should be included; * Suspected or confirmed history of alcohol or drug abuse; * Pregnant women, lactating women, or women of childbearing age who are preparing to conceive; Female subjects of childbearing age or male subjects (with partners of childbearing age) who do not agree to voluntarily take effective contraceptive measures within one month after the last dose during the screening period; * Individuals who are allergic to the drugs or their components used in this experiment; * Participants who have participated in other clinical trials within the past month; * The researchers believe that participants should not participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in best corrected visual acuity (BCVA) from baseline after 24 weeks of medication; | From enrollment to the end of treatment at 24 weeks | After 24 weeks of medication, the subjects' best corrected visual acuity (BCVA) was checked and compared with the value measured at week 0 to observe the degree of change from baseline value; |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in retinal macular optical coherence tomography (OCT) compared to baseline | From enrollment to the end of treatment at 12 and 24 weeks. | Changes in retinal macular optical coherence tomography(OCT) after 12 and 24 weeks of medication compared to baseline |
| Change in best corrected visual acuity (BCVA) from baseline after medication | From enrollment to the end of treatment at 4 weeks,8weeks,12weeks,16weeks,20weeks | After 4 weeks,8weeks,12weeks,16weeks,20weeks of medication, the subjects' best corrected visual acuity (BCVA) was checked separately and compared with the value measured at week 0 to observe the degree of change from baseline value; |
| The change and progression rate of ETDRS classification DR Classification from baseline after 12 and 24 weeks of medication; | From enrollment to the end of treatment at 12weeks and 24weeks. | After 12 weeks，24 weeks of medication, the subjects' ETDRS classification based on the Diabetic Retinopathy Severity Score and compared with the value measured at week 0 to observe the change and progression rate from baseline value as required, with a minimum score of 10 and a maximum score of 90. The higher the score, the more severe it is. |
| The proportion of subjects whose best corrected visual acuity (BCVA)increased by ≥ 5, ≥ 10, ≥ 15 compared to baseline after medication; | From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks | After 4,8,12,16,20,24 weeks of medication, count the proportion of subjects whose best corrected visual acuity(BCVA) increased by ≥ 5, ≥ 10, ≥ 15 compared to baseline |
| Changes in fundus condition compared to baseline | From enrollment to the end of treatment at 12 and 24 weeks. | Changes in fundus condition compared to baseline after 12 and 24 weeks of medication |
| Changes in HemoglobinA1c compared to baseline | From enrollment to the end of treatment at 12 and 24 weeks. | Changes in HemoglobinA1c levels compared to baseline after 12 and 24 weeks of medication |
| Changes in fasting blood glucose compared to baseline | From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks | Changes in fasting blood glucose levels after 4, 8, 12, 16, 20, and 24 weeks of medication compared to baseline |
| Effective rate of traditional Chinese medicine syndrome | From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks | After medication, use the Traditional Chinese Medicine Syndrome（yin deficiency with internal heat and blood stasis obstructing the collaterals of the eyes） Scale as required to score and calculate the effective rate,the lowest score is 0, the highest score is 30, and the higher the score, the more severe it is. |
| The proportion of subjects whose best corrected visual acuity (BCVA) decreased by ≥ 5, ≥ 10, ≥ 15 compared to baseline after medication | From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks | After 4,8,12,16,20,24 weeks of medication, count the proportion of subjects whose best corrected visual acuity(BCVA) decreased by ≥ 5, ≥ 10, ≥ 15 compared to baseline |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse events and reactions | From enrollment to the end of treatment at 24 weeks | Record adverse events, including number of participants with abnormal vital signs,urine analysis, urinalysis,liver function , etc |
Countries
China
Contacts
Primary ContactJinxin Clinical Project Manager
Outcome results
None listed